Drug Profile

Ceralasertib - AstraZeneca/University of Pennsylvania

Alternative Names: AZD 6738

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca; University of Pennsylvania
Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
Mechanism of Action ATR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Non-small cell lung cancer
Phase II Cholangiocarcinoma; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Phase I/II Chronic lymphocytic leukaemia
Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Preclinical Diffuse large B cell lymphoma; Type 1 diabetes mellitus
Discontinued Haematological malignancies; Non-Hodgkin's lymphoma; Squamous cell cancer

21 May 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in United Kingdom (PO) (NCT06929260)
22 Apr 2025 AstraZeneca plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) (PO) in April 2025(NCT06929260)
23 Dec 2024 AstraZeneca plans a phase I trial for Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer in United Kingdom(PO) In January 2025 (NCT06754761)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com